Eintrag weiter verarbeiten
Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study.
Gespeichert in:
| Zeitschriftentitel: | Journal of Clinical Oncology |
|---|---|
| Personen und Körperschaften: | , , , , , , , , |
| In: | Journal of Clinical Oncology, 30, 2012, 4_suppl, S. 566-566 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society of Clinical Oncology (ASCO)
|
| Schlagwörter: |
| author_facet |
Hofheinz, Ralf Grothe, Wilfried Tummes, Dirk Kindler, Manfred Petersen, Volker Boszeit-Luft, Stefanie Seraphin, Joerg Hinke, Axel Arnold, Dirk Hofheinz, Ralf Grothe, Wilfried Tummes, Dirk Kindler, Manfred Petersen, Volker Boszeit-Luft, Stefanie Seraphin, Joerg Hinke, Axel Arnold, Dirk |
|---|---|
| author |
Hofheinz, Ralf Grothe, Wilfried Tummes, Dirk Kindler, Manfred Petersen, Volker Boszeit-Luft, Stefanie Seraphin, Joerg Hinke, Axel Arnold, Dirk |
| spellingShingle |
Hofheinz, Ralf Grothe, Wilfried Tummes, Dirk Kindler, Manfred Petersen, Volker Boszeit-Luft, Stefanie Seraphin, Joerg Hinke, Axel Arnold, Dirk Journal of Clinical Oncology Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. Cancer Research Oncology |
| author_sort |
hofheinz, ralf |
| spelling |
Hofheinz, Ralf Grothe, Wilfried Tummes, Dirk Kindler, Manfred Petersen, Volker Boszeit-Luft, Stefanie Seraphin, Joerg Hinke, Axel Arnold, Dirk 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.4_suppl.566 <jats:p> 566 </jats:p><jats:p> Background: In most patients (pts) with metastatic colorectal cancer, a 3-drug combination of a fluoropyrimidine, oxaliplatin (ox) or irinotecan (iri), and a monoclonal antibody is considered standard 1st-line treatment. However, in elderly pts this choice remains controversial. After registration of bevacizumab (bev) in Germany in 2005, this observational study was initiated in pts receiving bev with various first-line chemotherapy (CT) regimens to evaluate the disease profile and efficacy of bev in patients with metastatic colorectal cancer. </jats:p><jats:p> Methods: Eligibility criteria focused on M1 disease without prior palliative CT. The choice of CT regimen was at the physician’s discretion. Predefined efficacy endpoints were: response rate (RR), progression-free survival (PFS) and overall survival (OS). Pts were followed for up to 6 years (y). Two pt subgroups were analyzed: ≥70 y and ≥75 y; the ≥75 y group is the focus of this abstract. </jats:p><jats:p> Results: 1777 eligible pts were enrolled at 261 sites from Jan 2005 to June 2009, 206 (12%) of whom were aged ≥75 y. These elderly pts did not differ greatly vs younger pts in time from initial diagnosis or time to first relapse, pT, pN and M stage, site of metastasis, grading, CEA, WBC, blood pressure, or prior adjuvant therapy. However, fewer elderly pts had >1 involved organ site (28% of pts ≥75 y vs. 32% of pts ≥70 y) and elderly pts had significantly poorer performance status (ECOG 0 in 29% of pts ≥75 y vs. 39% of pts ≥70 y). Bev treatment duration was similar in elderly and younger pts, but differences in CT usage were observed (Table). Response and survival outcomes were significantly worse in those aged ≥75 y. </jats:p><jats:p> Conclusions: Bev-based treatment combinations can be used successfully in pts aged ≥75 y. However, PFS and OS are significantly shorter in pts aged ≥75 y vs younger pts, probably because of greater comorbidity and possibly because of less intensive treatment in the elderly. </jats:p><jats:p> [Table: see text] </jats:p> Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. Journal of Clinical Oncology |
| doi_str_mv |
10.1200/jco.2012.30.4_suppl.566 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC40X3N1cHBsLjU2Ng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC40X3N1cHBsLjU2Ng |
| institution |
DE-Pl11 DE-Rs1 DE-14 DE-105 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Zi4 DE-Gla1 DE-15 |
| imprint |
American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv |
American Society of Clinical Oncology (ASCO), 2012 |
| issn |
0732-183X 1527-7755 |
| issn_str_mv |
0732-183X 1527-7755 |
| language |
English |
| mega_collection |
American Society of Clinical Oncology (ASCO) (CrossRef) |
| match_str |
hofheinz2012bevacizumabinthefirstlinetreatmentofelderlypatientswithmetastaticcolorectalcancermatureresultsfromalargecommunitybasedobservationalstudy |
| publishDateSort |
2012 |
| publisher |
American Society of Clinical Oncology (ASCO) |
| recordtype |
ai |
| record_format |
ai |
| series |
Journal of Clinical Oncology |
| source_id |
49 |
| title |
Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_unstemmed |
Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_full |
Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_fullStr |
Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_full_unstemmed |
Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_short |
Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_sort |
bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: mature results from a large community-based observational study. |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1200/jco.2012.30.4_suppl.566 |
| publishDate |
2012 |
| physical |
566-566 |
| description |
<jats:p> 566 </jats:p><jats:p> Background: In most patients (pts) with metastatic colorectal cancer, a 3-drug combination of a fluoropyrimidine, oxaliplatin (ox) or irinotecan (iri), and a monoclonal antibody is considered standard 1st-line treatment. However, in elderly pts this choice remains controversial. After registration of bevacizumab (bev) in Germany in 2005, this observational study was initiated in pts receiving bev with various first-line chemotherapy (CT) regimens to evaluate the disease profile and efficacy of bev in patients with metastatic colorectal cancer. </jats:p><jats:p> Methods: Eligibility criteria focused on M1 disease without prior palliative CT. The choice of CT regimen was at the physician’s discretion. Predefined efficacy endpoints were: response rate (RR), progression-free survival (PFS) and overall survival (OS). Pts were followed for up to 6 years (y). Two pt subgroups were analyzed: ≥70 y and ≥75 y; the ≥75 y group is the focus of this abstract. </jats:p><jats:p> Results: 1777 eligible pts were enrolled at 261 sites from Jan 2005 to June 2009, 206 (12%) of whom were aged ≥75 y. These elderly pts did not differ greatly vs younger pts in time from initial diagnosis or time to first relapse, pT, pN and M stage, site of metastasis, grading, CEA, WBC, blood pressure, or prior adjuvant therapy. However, fewer elderly pts had >1 involved organ site (28% of pts ≥75 y vs. 32% of pts ≥70 y) and elderly pts had significantly poorer performance status (ECOG 0 in 29% of pts ≥75 y vs. 39% of pts ≥70 y). Bev treatment duration was similar in elderly and younger pts, but differences in CT usage were observed (Table). Response and survival outcomes were significantly worse in those aged ≥75 y. </jats:p><jats:p> Conclusions: Bev-based treatment combinations can be used successfully in pts aged ≥75 y. However, PFS and OS are significantly shorter in pts aged ≥75 y vs younger pts, probably because of greater comorbidity and possibly because of less intensive treatment in the elderly. </jats:p><jats:p> [Table: see text] </jats:p> |
| container_issue |
4_suppl |
| container_start_page |
566 |
| container_title |
Journal of Clinical Oncology |
| container_volume |
30 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792327820062490632 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:43:28.571Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Bevacizumab+in+the+first-line+treatment+of+elderly+patients+with+metastatic+colorectal+cancer%3A+Mature+results+from+a+large+community-based+observational+study.&rft.date=2012-02-01&genre=article&issn=1527-7755&volume=30&issue=4_suppl&spage=566&epage=566&pages=566-566&jtitle=Journal+of+Clinical+Oncology&atitle=Bevacizumab+in+the+first-line+treatment+of+elderly+patients+with+metastatic+colorectal+cancer%3A+Mature+results+from+a+large+community-based+observational+study.&aulast=Arnold&aufirst=Dirk&rft_id=info%3Adoi%2F10.1200%2Fjco.2012.30.4_suppl.566&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792327820062490632 |
| author | Hofheinz, Ralf, Grothe, Wilfried, Tummes, Dirk, Kindler, Manfred, Petersen, Volker, Boszeit-Luft, Stefanie, Seraphin, Joerg, Hinke, Axel, Arnold, Dirk |
| author_facet | Hofheinz, Ralf, Grothe, Wilfried, Tummes, Dirk, Kindler, Manfred, Petersen, Volker, Boszeit-Luft, Stefanie, Seraphin, Joerg, Hinke, Axel, Arnold, Dirk, Hofheinz, Ralf, Grothe, Wilfried, Tummes, Dirk, Kindler, Manfred, Petersen, Volker, Boszeit-Luft, Stefanie, Seraphin, Joerg, Hinke, Axel, Arnold, Dirk |
| author_sort | hofheinz, ralf |
| container_issue | 4_suppl |
| container_start_page | 566 |
| container_title | Journal of Clinical Oncology |
| container_volume | 30 |
| description | <jats:p> 566 </jats:p><jats:p> Background: In most patients (pts) with metastatic colorectal cancer, a 3-drug combination of a fluoropyrimidine, oxaliplatin (ox) or irinotecan (iri), and a monoclonal antibody is considered standard 1st-line treatment. However, in elderly pts this choice remains controversial. After registration of bevacizumab (bev) in Germany in 2005, this observational study was initiated in pts receiving bev with various first-line chemotherapy (CT) regimens to evaluate the disease profile and efficacy of bev in patients with metastatic colorectal cancer. </jats:p><jats:p> Methods: Eligibility criteria focused on M1 disease without prior palliative CT. The choice of CT regimen was at the physician’s discretion. Predefined efficacy endpoints were: response rate (RR), progression-free survival (PFS) and overall survival (OS). Pts were followed for up to 6 years (y). Two pt subgroups were analyzed: ≥70 y and ≥75 y; the ≥75 y group is the focus of this abstract. </jats:p><jats:p> Results: 1777 eligible pts were enrolled at 261 sites from Jan 2005 to June 2009, 206 (12%) of whom were aged ≥75 y. These elderly pts did not differ greatly vs younger pts in time from initial diagnosis or time to first relapse, pT, pN and M stage, site of metastasis, grading, CEA, WBC, blood pressure, or prior adjuvant therapy. However, fewer elderly pts had >1 involved organ site (28% of pts ≥75 y vs. 32% of pts ≥70 y) and elderly pts had significantly poorer performance status (ECOG 0 in 29% of pts ≥75 y vs. 39% of pts ≥70 y). Bev treatment duration was similar in elderly and younger pts, but differences in CT usage were observed (Table). Response and survival outcomes were significantly worse in those aged ≥75 y. </jats:p><jats:p> Conclusions: Bev-based treatment combinations can be used successfully in pts aged ≥75 y. However, PFS and OS are significantly shorter in pts aged ≥75 y vs younger pts, probably because of greater comorbidity and possibly because of less intensive treatment in the elderly. </jats:p><jats:p> [Table: see text] </jats:p> |
| doi_str_mv | 10.1200/jco.2012.30.4_suppl.566 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTIwMC9qY28uMjAxMi4zMC40X3N1cHBsLjU2Ng |
| imprint | American Society of Clinical Oncology (ASCO), 2012 |
| imprint_str_mv | American Society of Clinical Oncology (ASCO), 2012 |
| institution | DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15 |
| issn | 0732-183X, 1527-7755 |
| issn_str_mv | 0732-183X, 1527-7755 |
| language | English |
| last_indexed | 2024-03-01T12:43:28.571Z |
| match_str | hofheinz2012bevacizumabinthefirstlinetreatmentofelderlypatientswithmetastaticcolorectalcancermatureresultsfromalargecommunitybasedobservationalstudy |
| mega_collection | American Society of Clinical Oncology (ASCO) (CrossRef) |
| physical | 566-566 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Society of Clinical Oncology (ASCO) |
| record_format | ai |
| recordtype | ai |
| series | Journal of Clinical Oncology |
| source_id | 49 |
| spelling | Hofheinz, Ralf Grothe, Wilfried Tummes, Dirk Kindler, Manfred Petersen, Volker Boszeit-Luft, Stefanie Seraphin, Joerg Hinke, Axel Arnold, Dirk 0732-183X 1527-7755 American Society of Clinical Oncology (ASCO) Cancer Research Oncology http://dx.doi.org/10.1200/jco.2012.30.4_suppl.566 <jats:p> 566 </jats:p><jats:p> Background: In most patients (pts) with metastatic colorectal cancer, a 3-drug combination of a fluoropyrimidine, oxaliplatin (ox) or irinotecan (iri), and a monoclonal antibody is considered standard 1st-line treatment. However, in elderly pts this choice remains controversial. After registration of bevacizumab (bev) in Germany in 2005, this observational study was initiated in pts receiving bev with various first-line chemotherapy (CT) regimens to evaluate the disease profile and efficacy of bev in patients with metastatic colorectal cancer. </jats:p><jats:p> Methods: Eligibility criteria focused on M1 disease without prior palliative CT. The choice of CT regimen was at the physician’s discretion. Predefined efficacy endpoints were: response rate (RR), progression-free survival (PFS) and overall survival (OS). Pts were followed for up to 6 years (y). Two pt subgroups were analyzed: ≥70 y and ≥75 y; the ≥75 y group is the focus of this abstract. </jats:p><jats:p> Results: 1777 eligible pts were enrolled at 261 sites from Jan 2005 to June 2009, 206 (12%) of whom were aged ≥75 y. These elderly pts did not differ greatly vs younger pts in time from initial diagnosis or time to first relapse, pT, pN and M stage, site of metastasis, grading, CEA, WBC, blood pressure, or prior adjuvant therapy. However, fewer elderly pts had >1 involved organ site (28% of pts ≥75 y vs. 32% of pts ≥70 y) and elderly pts had significantly poorer performance status (ECOG 0 in 29% of pts ≥75 y vs. 39% of pts ≥70 y). Bev treatment duration was similar in elderly and younger pts, but differences in CT usage were observed (Table). Response and survival outcomes were significantly worse in those aged ≥75 y. </jats:p><jats:p> Conclusions: Bev-based treatment combinations can be used successfully in pts aged ≥75 y. However, PFS and OS are significantly shorter in pts aged ≥75 y vs younger pts, probably because of greater comorbidity and possibly because of less intensive treatment in the elderly. </jats:p><jats:p> [Table: see text] </jats:p> Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. Journal of Clinical Oncology |
| spellingShingle | Hofheinz, Ralf, Grothe, Wilfried, Tummes, Dirk, Kindler, Manfred, Petersen, Volker, Boszeit-Luft, Stefanie, Seraphin, Joerg, Hinke, Axel, Arnold, Dirk, Journal of Clinical Oncology, Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study., Cancer Research, Oncology |
| title | Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_full | Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_fullStr | Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_full_unstemmed | Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_short | Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| title_sort | bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: mature results from a large community-based observational study. |
| title_unstemmed | Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1200/jco.2012.30.4_suppl.566 |